Insider Transactions in Q2 2022 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 15
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.38%
|
$390,000
$39.4 P/Share
|
|
Jun 15
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.33%
|
$70,000
$7.96 P/Share
|
|
Jun 09
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
21,500
-11.33%
|
$860,000
$40.62 P/Share
|
|
Jun 09
2022
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
21,500
+10.17%
|
$193,500
$9.65 P/Share
|
|
Jun 06
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.38%
|
$410,000
$41.23 P/Share
|
|
Jun 06
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.33%
|
$70,000
$7.96 P/Share
|
|
May 16
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.39%
|
$430,000
$43.11 P/Share
|
|
May 16
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.33%
|
$70,000
$7.96 P/Share
|
|
May 12
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
13,987
-7.68%
|
$517,519
$37.54 P/Share
|
|
May 12
2022
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
13,987
+7.13%
|
$125,883
$9.65 P/Share
|
|
May 10
2022
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+32.18%
|
-
|
|
May 10
2022
|
Santo J Costa Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+33.33%
|
-
|
|
May 10
2022
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
May 10
2022
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+17.51%
|
-
|
|
May 10
2022
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+28.9%
|
-
|
|
May 10
2022
|
B Lynne Parshall Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+33.33%
|
-
|
|
May 10
2022
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+29.35%
|
-
|
|
May 10
2022
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+29.35%
|
-
|
|
May 10
2022
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.96%
|
-
|
|
May 04
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.39%
|
$390,000
$39.43 P/Share
|
|
May 04
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.33%
|
$70,000
$7.96 P/Share
|
|
Apr 20
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.39%
|
$370,000
$37.89 P/Share
|
|
Apr 20
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.33%
|
$70,000
$7.96 P/Share
|
|
Apr 07
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
23,148
-12.1%
|
$972,216
$42.58 P/Share
|
|
Apr 07
2022
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
23,148
+10.8%
|
$138,888
$6.0 P/Share
|
|
Apr 05
2022
|
Ching Jaw SVP Finance & CFO |
SELL
Open market or private sale
|
Direct |
10,000
-12.97%
|
$420,000
$42.0 P/Share
|
|
Apr 05
2022
|
Ching Jaw SVP Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.48%
|
$120,000
$12.1 P/Share
|
|
Apr 04
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.39%
|
$380,000
$38.78 P/Share
|
|
Apr 04
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.33%
|
$70,000
$7.96 P/Share
|
|
Apr 04
2022
|
Ching Jaw SVP Finance & CFO |
SELL
Open market or private sale
|
Direct |
15,000
-18.27%
|
$600,000
$40.0 P/Share
|
|
Apr 04
2022
|
Ching Jaw SVP Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+15.45%
|
$180,000
$12.1 P/Share
|
|
Apr 01
2022
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
293
+5.03%
|
$11,134
$38.38 P/Share
|
|
Apr 01
2022
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
488
+2.56%
|
$18,544
$38.38 P/Share
|
|
Apr 01
2022
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
293
+3.86%
|
$11,134
$38.38 P/Share
|
|
Apr 01
2022
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
146
+2.03%
|
$5,548
$38.38 P/Share
|
|
Apr 01
2022
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
146
+2.03%
|
$5,548
$38.38 P/Share
|
|
Apr 01
2022
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
146
+2.32%
|
$5,548
$38.38 P/Share
|